Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700440 | 0.87 | SLC22A12 (0.43) | SLC22A12CA12CA2CA9CA1 | |
| SCHEMBL5700433 | 0.81 | CA12 (0.40) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5700164 | 0.76 | CA12 (0.37) | SLC22A12CA12CA2CA9CA1 | |
| SCHEMBL14494474 | 0.74 | SLC22A12 (0.40) | SLC22A12HTTKMT2AALDH1A1MEN1 | |
| SCHEMBL8148133 | 0.72 | CA12 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL19144940 | 0.72 | L3MBTL1 (0.44) | CA12CA2CA9CA1CA14 | |
| SCHEMBL514821 | 0.72 | ALDH1A1 (0.63) | SLC22A12HTTALDH1A1 | |
| SCHEMBL2646684 | 0.72 | CA12 (0.39) | SLC22A12CA12CA2CA9CA1 | |
| SCHEMBL5700467 | 0.72 | CA12 (0.39) | CA12CA2CA9CA1CA14 | |
| SCHEMBL15823128 | 0.72 | RARB (0.42) | CA12CA2CA9HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220104493-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2022-04-07 | — | — | US | disclosed |
| EP-3920701-A1 | HERBICIDAL COMPOUNDS | Syngenta Crop Protection AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| CN-113412055-A | Herbicidal compounds | 先正达农作物保护股份公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020161163-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020161163-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220104493-A1 | HERBICIDAL COMPOUNDS | DDT, ACHE, GSTO1 | SLC22A12 1814/4885CA12 2083/4885CA2 257/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | SLC22A12 4178/4885CA12 1841/4885CA2 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.